Targeting mitochondria for cancer therapy

Environmental and Molecular Mutagenesis

Volumn 51, Issue 5, 2010, Pages 476-489

  Hockenbery, David M ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Apoptosis; Bcl 2; BH3; Mitochondria; PTP

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 3 [3' (1 ADAMANTYL) 4' HYDROXYBIPHENYL 4 YL]ACRYLIC ACID; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; 4 [4 [2 (4 CHLOROPHENYL) 5,5 DIMETHYL 1 CYCLOHEXEN 1 YLMETHYL] 1 PIPERAZINYL] N [4 [3 MORPHOLINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 (TRIFLUOROMETHYLSULFONYL)BENZENESULFONYL]BENZAMIDE; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BISPHOSPHONIC ACID DERIVATIVE; BROMOPYRUVIC ACID; CHELERYTHRINE; DICHLOROACETIC ACID; DITERCALINIUM; GLUCOSE; GLUTAMINE; GOSSYPOL; HA 141; METFORMIN; MITOCHONDRIAL DNA; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; OBATOCLAX; PHENETHYL ISOTHIOCYANATE; PROTEIN BCL 2; PROTEIN BCL W; PROTEIN BCL XL; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; SANGUINARINE; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; ANAEROBIC GLYCOLYSIS; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ATAXIA; BREAST ADENOCARCINOMA; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CELL STRESS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DIABETES MELLITUS; DIARRHEA; DISEASE ASSOCIATION; DRUG DOSE COMPARISON; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TARGETING; DYSPHORIA; ENDOPLASMIC RETICULUM; FOLLICULAR LYMPHOMA; HEAD AND NECK CANCER; HUMAN; HYPERPOLARIZATION; LEUKEMIA; LUNG SMALL CELL CANCER; LYMPHOMA; MITOCHONDRION; NAUSEA; NONHODGKIN LYMPHOMA; ONCOGENE; OVARY CANCER; PROMYELOCYTIC LEUKEMIA; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SMALL INTESTINE OBSTRUCTION; SOMNOLENCE; SQUAMOUS CELL CARCINOMA;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; HUMANS; MITOCHONDRIA; NEOPLASMS; PEPTIDE FRAGMENTS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 77953494288     PISSN: 08936692     EISSN: 10982280     Source Type: Journal    
DOI: 10.1002/em.20552     Document Type: Review

References (147)

1. Amundson SA, Myers TG, Scudiero D, Kitada S, Reed JC, Fornace AJ Jr. 2000. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res 60:6101-6110.
2. Antonsson B, Martinou JC. 2000. The Bcl-2 protein family. Exp Cell Res 256:50-57.
3. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod JJ, Mazzei G, Maundrell K, Gambale F, Sadoul R, Martinou JC. 1997. Inhibition of Bax channel-forming activity by Bcl-2. Science 277:370-372. (Pubitemid 27450709)
4. Bakhshi A, Jensen JP, Goldman P, Wright JJ, McBride OW, Epstein AL, Korsmeyer SJ. 1985. Cloning the chromosomal breakpoint of t(14;18) human lymphomas: Clustering around JH on chromosome 14 and near a transcriptional unit on 18. Cell 41:899-906. (Pubitemid 15243395)
5. Barnhart BC, Lee JC, Alappat EC, Peter ME. 2003. The death effector domain protein family. Oncogene 22:8634-8644.
6. Becattini B, Kitada S, Leone M, Monosov E, Chandler S, Zai D, Kipps TJ, Reed JC, Pellecchia M. 2004. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-xL. Chem Biol 11:389-395.
7. Bellamy CO, Malcomson RD, Harrison DJ, Wyllie AH. 1995. Cell death in health and disease: The biology and regulation of apoptosis. Semin Cancer Biol 6:3-16.
8. Benard J, Bettan-Renaud L, Gavoille A, Pico JL, Beaujean F, Lopez M, Riou G. 1988. In vitro chemical eradication of small cell lung cancer: Application in autologous bone marrow transplantation. Eur J Cancer Clin Oncol 24:1561-1566.
9. Bental M, Deutsch C. 1993. Metabolic changes in activated T cells: An NMR study of human peripheral blood lymphocytes. Magn Reson Med 29:317-326. (Pubitemid 23114497)
10. Bersin RM, Wolfe C, Kwasman M, Lau D, Klinski C, Tanaka K, Khorrami P, Henderson GN, de Marco T, Chatterjee K. 1994. Improved hemodynamic function and mechanical efficiency in congestive heart failure with sodium dichloroacetate. J Am Coll Cardiol 23:1617-1624. (Pubitemid 24182128)
11. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R, Lee CT, Lopaschuk GD, Puttagunta L, Bonnet S, Harry G, Hashimoto K, Porter CJ, Andrade MA, Thebaud B, Michelakis ED. 2007. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 11:37-51.
12. Bowker SL, Majumdar SR, Veugelers P, Johnson JA. 2006. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254-258.
13. Brown KK, Eriksson SE, Arnér ES, Hampton MB. 2008. Mitochondrial peroxiredoxin 3 is rapidly oxidized in cells treated with isothiocyanates. Free Radic Biol Med 45:494-502.
14. Bushunow P, Reidenberg MM, Wasenko J, Winfield J, Lorenzo B, Lemke S, Himpler B, Corona R, Coyle T. 1999. Gossypol treatment of recurrent adult malignant gliomas. J Neurooncol 43:79-86.
15. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, Deberardinis RJ, Zhao F, Viollet B, Thompson CB. 2007. Systemic treatment with the anti-diabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67:6745-6752.
16. Chan SL, Lee MC, Tan KO, Yang LK, Lee AS, Flotow H, Fu NY, Butler MS, Soejarto DD, Buss AD, Yu VC. 2003. Identification of chelerythrine as an inhibitor of BclXL function. J Biol Chem 278:20453-20456.
17. Chen S, Dai Y, Harada H, Dent P, Grant S. 2007. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res 67:782-791.
18. Chittenden T, Flemington C, Houghton AB, Ebb RG, Gallo GJ, Elangovan B, Chinnadurai G, Lutz RJ. 1995. A conserved domain in Bak, distinct from BH1 and BH2, mediates cell death and protein binding functions. EMBO J 14:5589-5596.
19. Cleary ML, Sklar J. 1985. Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 82:7439-7443.
20. Costantini P, Belzacq AS, Vieira HL, Larochette N, de Pablo MA, Zamzami N, Susin SA, Brenner C, Kroemer G. 2000. Oxidation of a critical thiol residue of the adenine nucleotide translocator enforces Bcl-2-independent permeability transition pore opening and apoptosis. Oncogene 19:307-314. (Pubitemid 30077228)
21. Coude FX, Saudubray JM, DeMaugre F, Marsac C.Leroux JP, Charpentier C. 1978. Dichloroacetate as treatment for congenital lactic acidosis. New Engl J Med 299:1365-1366. (Pubitemid 9106168)
22. Dang CV. 2009. MYC-induced cancer cell energy metabolism and therapeutic opportunities. Clin Cancer Res 15:6479-6483.
23. Davis S, Weiss MJ, Wong JR, Lampidis TJ, Chen LB. 1985. Mitochondrial and plasma membrane potentials cause unusual accumulation and retention of rhodamine 123 by human breast adenocarcinoma-derived MCF-7 cells. J Biol Chem 260:13844-13850. (Pubitemid 16233244)
24. Day CL, Chen L, Richardson SJ, Harrison PJ, Huang DC, Hinds MG. 2005. Solution structure of prosurvival Mcl-1 and characterization of its binding by proapoptotic BH3-only ligands. J Biol Chem 280:4738-4744.
25. Degterev A, Lugovskoy A, Cardone M, Mulley B, Wagner G, Mitchison T, Yuan J. 2001. Identification of small-molecule inhibitors of interaction between the BH3 domain and Bcl-xL. Nat Cell Biol 3:173-182.
26. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. 2007. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 117:112-121.
27. Diel IJ, Solomayer EF, Costa SD, Gollan C, Goerner C, Wallwiener D, Kaufmann M, Bastert G. 1998. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 339:357-363.
28. Dodou K, Anderson RJ, Small DA, Groundwater PW. 2005. Investigations on gossypol: Past and present developments. Expert Opin Invest Drugs 14:1419-1434.
29. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. 2005. Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305.
30. Fantin VR, Berardi MJ, Scorrano L, Korsmeyer SJ, Leder P. 2002. A novel mitochondriotoxic small molecule that selectively inhibits tumor cell growth. Cancer Cell 2:29-42.
31. Feng WY, Liu FT, Patwari Y, Agrawal SG, Newland AC, Jia L. 2003. BH3-domain mimetic compound BH3I-2′ induces rapid damage to the inner mitochondrial membrane prior to the cytochrome c release from mitochondria. Br J Haematol 121:332-340.
32. Fesik SW. 2000. Insights into programmed cell death through structural biology. Cell 103:273-282.
33. Flack MR, Pyle RG, Mullen NM, Lorenzo B, Wu YW, Knazek RA, Nisula BC, Reidenberg MM. 1993. Oral gossypol in the treatment of metastatic adrenal carcinoma. J Clin Endocrinol Metab 76:1019-1024.
34. Fumarola C, Guidotti GG. 2004. Stress-induced apoptosis: Toward a symmetry with receptor-mediated cell death. Apoptosis 9:77-82.
35. Gavathiotis E, Suzuki M, Davis ML, Pitter K, Bird GH, Katz SG, Tu HC, Kim H, Cheng EH, Tjandra N, Walensky LD. 2008. BAX activation is initiated at a novel interaction site. Nature 455:1076-1081.
36. Grenby TH. 1995. The use of sanguinarine in mouthwashes and toothpaste compared with some other antimicrobial agents. Br Dent J 178:254-258.
37. Han YH, Cao X, Lin B, Lin F, Kolluri SK, Stebbins J, Reed JC, Dawson MI, Zhang XK. 2006. Regulation of Nur77 nuclear export by c-Jun N-terminal kinase and Akt. Oncogene 25:2974-2986.
38. Hao JH, Yu M, Liu FT, Newland AC, Jia L. 2004. Bcl-2 inhibitors sensitize tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by uncoupling of mitochondrial respiration in human leukemic CEM cells, Cancer Res 64:3607-3616.
39. Hawley SA, Gadalla AE, Olsen GS, Hardie DG. 2002. The antidiabetic drug metformin activates the AMP-activated protein kinase cascade via an adenine nucleotide-independent mechanism. Diabetes 51:2420-2425.
40. He X, Ma Q. 2010. Critical cystein residues of Kelch-like ECH-associated protein 1 in arsenic-sensing and suppression of nuclear factor erythroid 2-related factor 2. J Pharmacol Exp Ther 32:66-75.
41. Hennet T, Bertoni G, Richter C, Peterhans E. 1993. Expression of BCL-2 protein enhances the survival of mouse fibrosarcoid cells in tumor necrosis factor-mediated cytotoxicity. Cancer Res 53:1456-1460. (Pubitemid 23097132)
42. Hinds MG, Smits C, Fredericks-Short R, Risk JM, Bailey M, Huang DC, Day CL. 2007. Bim, Bad and Bmf: Intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ 14:128-136.
43. Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K. 2009. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69:7507-7511.
44. Holmes WF, Soprano DR, Soprano KJ. 2003. Early event in the induction of apoptosis in ovarian carcinoma cells by CD437: Activation of the p38 MAP kinase signal pathway. Oncogene 22:6377-6386.
45. Houghton FD, Thompson JG, Kennedy CJ, Leese HJ. 1996. Oxygen consumption and energy metabolism of the early mouse embryo. Mol Reprod Dev 44:476-485.
46. Huang DC, Strasser A. 2000. BH3-Only proteins-essential initiators of apoptotic cell death. Cell 103:839-842.
47. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM. 2009. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302.
48. Kay BK, Hamilton PT. 2001. Identification of enzyme inhibitors from phage-displayed combinatorial peptide libraries. Comb Chem High Throughput Screen 4:535-543.
49. Kim KM, Giedt CD, Basañez G, O'Neill JW, Hill JJ, Han YH, Tzung SP, Zimmerberg J, Hockenbery DM, Zhang KY. 2001. Biophysical characterization of recombinant Bcl-2 and its interactions with an inhibitory ligand, antimycin A. Biochemistry 40:4911-4922.
50. Kitada S, Leone M, Sareth S, Zhai D, Reed JC, Pellecchia M. 2003. Discovery, characterization, and structure-activity relationships studies of proapoptotic polyphenols targeting B-cell lymphocyte/leukemia-2 proteins. J Med Chem 46:4259-4264.
51. Ko YH, Pedersen PL, Geschwind JF. 2001. Glucose catabolism in the rabbit VX2 tumor model for liver cancer: Characterization and targeting hexokinase. Cancer Lett 173:83-91.
52. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, Hullihen J, Pedersen PL. 2004. Advanced cancers: Eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 324:269-275.
53. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreef M. 2006. Mechanisms of apoptosis selectivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 10:375-388.
54. Kornbluth S, White K. 2005. Apoptosis in Drosophila: Neither fish nor fowl (nor man, nor worm). J Cell Sci 118:1779-1787.
55. Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR, Newmeyer DD. 2005. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 17:525-535.
56. Lacapere JJ, Papadopoulos V. 2003. Peripheral-type benzodiazepine receptor: Structure and function of a cholesterol-binding protein in steroid and bile acid synthesis. Steroids 68:569-585.
57. Lee EF, Czabotar PE, Smith BJ, Deshayes K, Zobel K, Colman PM, Fairlie WD. 2007. Crystal structure of ABT-737 complexed with Bcl-xL: Implications for selectivity of antagonists of the Bcl-2 family. Cell Death Differ 14:1711-1713.
58. Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE. 2002. Further insight into mechanism of action of clodronate: Inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255-1262.
59. Lei X, Chen Y, Du G, Yu W, Wang X, Qu H, Xia B, He H, Mao J, Zong W, Liao X, Mehrpour M, Hao X, Chen Q. 2006. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via a conformation change in Bcl-2. FASEB J 20:2147-2149.
60. Le Moyec L, Naruse S, Higuchi T, Hirakawa K, Watari H, de Certaines JD, Roques BP. 1988. In vivo 31P MRS in new antineoplastic agents evaluation on experimental tumor models. Cancer Biochem Biophys 10:31-45.
61. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ. 2002. Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2:183-192.
62. Li H, Zhu H, Xu CJ, Yuan J. 1998. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94:491-501. (Pubitemid 28391865)
63. Li L, Wang J, Ye RD, Shi G, Jin H, Tang X, Yi J. 2008. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase. J Cell Physiol 217:486-493.
64. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. 2009. New users of metformin are at low risk of incident cancer: A cohort study among people with type 2 diabetes. Diabetes Care 32:1620-1625.
65. Lin B, Kolluri SK, Lin F, Han YH, Cao X, Dawson MI, Reed JC, Zhang XK. 2004. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 116:527-540.
66. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA, Fesik SW, Shen Y. 2007. 'Seed' analysis of off-target siRNAs revelas an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26:3972-3979.
67. Liu G, Kelly WK, Wilding G, Leopold L, Brill K, Somer B. 2009. An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 15:3172-3176.
68. Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA. 2008. Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program. Pediatr Blood Cancer 50:1181-1189. (Pubitemid 351555542)
69. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. 1998. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94:481-490. (Pubitemid 28391864)
70. Manero F, Gautier F, Gallenne T, Cauquil N, Gree D, Cartron PF, Geneste O, Gree R, Vallette FM, Juin P. 2006. The small organic compound HA14-1 prevents Bcl-2 interaction with Bax to sensitize malignant glioma cells to induction of cell death. Cancer Res 66:2757-2764.
71. Manion MK, O'Neill JW, Giedt CD, Kim KM, Zhang KY, Hockenbery DM. 2004. Bcl-XL mutations suppress cellular sensitivity to antimycin A. J Biol Chem 279:2159-2165.
72. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW, Huang DC, Kile BT. 2007. Programmed anuclear cell death delimits platelet life span. Cell 128:1173-1186.
73. Mathupala SP, Ko YH, Pedersen PL. 2006. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 25:4777-4786.
74. Mayr GW, Windhorst S, Hillemeier K. 2005. Antiproliferative plant and synthetic polyphenolics are specific inhibitors of vertebrate inositol-1,4,5-trisphosphate 3-kinases and inositol polyphosphate multikinase. J Biol Chem 280:13229-13240.
75. McDonnell TJ, Korsmeyer SJ. 1991. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). Nature 349:254-256.
76. McEnery MW, Snowman AM, Trifiletti RR, Snyder SH. 1992. Isolation of the mitochondrial benzodiazepine receptor: Association with the voltage-dependent anion channel and the adenine nucleotide carrier. Proc Natl Acad Sci USA 89:3170-3174.
77. Milanesi E, Costantini P, Gambalunga A, Colonna R, Petronilli V, Cabrelle A, Semenzato G, Cesura AM, Pinard E, Bernardi P. 2006. The mitochondrial effects of small organic ligands of BCL-2: Sensitization of BCL-2-overexpressing cells to apoptosis by a pyrimidine-2,4,6-trione derivative. J Biol Chem 281:10066-10072.
78. Minn AJ, Rudin CM, Boise LH, Thompson CB. 1995. Expression of bcl-xL can confer a multidrug resistance phenotype. Blood 86:1903-1910.
79. Minn AJ, Vélez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB. 1997. Bcl-xL forms an ion channel in synthetic lipid membranes. Nature 385:353-357.
80. Mitsiades CS, Hayden P, Kotoula V, McMillin DW, McMullen C, Negri J, Delmore JE, Poulaki V, Mitsiades N. 2007. Bcl-2 overexpression in thyroid carcinoma cells increases sensitivity to Bcl-2 homology 3 domain inhibition, J Clin Endocrinol Metab 92:4845-4852.
81. Modica-Napolitano JS, Aprille JR. 2001. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 49:63-70.
82. Mönkkönen H, Auriola S, Lehenkari P, Kellinsalmi M, Hassinen IE, Vepsäläinen J, Mönkkönen J. 2006. A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates. Br J Pharmacol 147:437-445.
83. Morrish F, Isern N, Sadilek M, Jeffrey M, Hockenbery D. 2009. c-Myc activates multiple metabolic networks to generate substrates for cell-cycle entry. Oncogene 28:2485-2491.
84. Muchmore SW, Sattler M, Liang H, Meadows RP, Harlan JE, Yoon HS, Nettesheim D, Chang BS, Thompson CB, Wong SL, Ng SL, Fesik SW. 1996. X-ray and NMR structure of human Bcl-xL, an inhibitor of programmed cell death. Nature 381:335-341.
85. Nakano K, Vousden KH. 2001. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 7:683-694.
86. Nicholson DW. 1999. Caspase structure, proteolytic substrates, and function during apoptotic cell death. Cell Death Differ 6:1028-1042.
87. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR, Goulet D, Viallet J, Bélec L, Billot X, Acoca S, Purisima E, Wiegmans A, Cluse L, Johnstone RW, Beauparlant P, Shore GC. 2007. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104:19512-19517.
88. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, Viallet J, Cheson BD. 2009. Phase I study of obatoclax (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood 113:299-305.
89. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T, Tanaka N. 2000. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 288:1053-1058.
90. Olejniczak ET, Van Sant C, Anderson MG, Wang G, Tahir SK, Sauter G, Lesniewski R, Semizarov D. 2007. Integrative genomic analysis of small-cell lung carcinoma reveals correlates of sensitivity to bcl-2 antagonists and uncovers novel chromosomal gains. Mol Cancer Res 5:331-339.
91. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, Zhang H, Fesik SW, Rosenberg SH. 2005. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435:677-681.
92. Oltvai ZN, Milliman CL, Korsmeyer SJ. 1993. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 74:609-619.
93. Owen MR, Doran E, Halestrap AP. 2000. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348:607-614.
94. Park SY, Cho N, Chang I, Chung JH, Min YK, Lee MK, Kim KW, Kim SJ, Lee MS. 2005. Effect of PK11195, a peripheral benzodiazepine receptor agonist, on insulinoma cell death and insulin secretion. Apoptosis 10:537-544.
95. Pelaprat D, Delbarre A, Le Guen I, Roques BP, Le Pecq JB. 1980. DNA intercalating compounds as potential antitumor agents. II. Preparation and properties of 7H-pyridocarbazole dimers. J Med Chem 23:1336-1343. (Pubitemid 11164101)
96. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, Da Polan AT, Galina A. 2009. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 417:717-726.
97. Pfahl M, Piedrafita FJ. 2003. Retinoid targets for apoptosis induction. Oncogene 8:9058-9062.
98. Powles T, Paterson S, Kanis JA, McCloskey E, Ashley S, Tidy A, Rosenqvist K, Smith I, Ottestad L, Legault S, Pajunen M, Nevantaus A, Männistö E, Suovuori A, Atula S, Nevalainen J, Pylkkänen L. 2002. Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol 20:3219-3224.
99. Riedl SJ, Salvesen GS. 2007. The apoptosome: Signaling platform of cell death. Nat Rev Mol Cell Biol 462:210-219.
100. Rone MB, Fan J, Papadopoulos V. 2009. Cholesterol transport in steroid biosynthesis: Role of protein-protein interactions and implications in disease states. Biochim Biophys Acta 1791:646-658.
101. Saito M, Korsmeyer SJ, Schlesinger PH. 2000. BAX-dependent transport of cytochrome c reconstituted in pure liposomes. Nat Cell Biol 2:553-555.
102. Sanborn BM, Felberg NT, Hollocher TC. 1971. The inactivation of succinate dehydrogenase by bromopyruvate. Biochim Biophys Acta 227:219-231.
103. Sattler M, Liang H, Nettesheim D, Meadows RP, Harlan JE, Eberstadt M, Yoon HS, Shuker SB, Chang BS, Minn AJ, Thompson CB, Fesik SW. 1997. Structure of Bcl-xL-Bak peptide complex: Recognition between regulators of apoptosis. Science 275:983-986.
104. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC. 1997. Channel formation by antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 94:5113-5118. (Pubitemid 27214745)
105. Schneider JA, Diamond I, Rozengurt E. 1978. Glycolysis of quiescent cultures of 3T3 cells. Addition of serum, epidermal growth factor, and insulin increases the activity of phosphofructokinase in a protein synthesis-independent manner. J Biol Chem 253:872-877. (Pubitemid 8271469)
106. Schwartz PS, Manion MK, Emerson CB, Fry JS, Schulz CM, Sweet IR, Hockenbery DM. 2007. 2-Methoxy antimycin reveals a unique mechanism for Bcl-xL inhibition. Mol Cancer Ther 6:2073-2080.
107. Scorrano L, Korsmeyer SJ. 2003. Mechanisms of cytochrome c release by proapoptotic BCL-2 family members. Biochem Biophys Res Commun 304:437-444.
108. Segal-Bendirdjian E, Coulaud D, Roques BP, Le Pecq JB. 1988. Selective loss of mitochondrial DNA after treatment of cells with ditercalinium (NSC 335153), an antitumor bis-intercalating agent. Cancer Res 48:4982-4992.
109. Shelley MD, Hartley L, Groundwater PW, Fish RG. 2000. Structure-activity studies on gossypol in tumor cell lines. Anticancer Drugs 11:209-216.
110. Shi Y. 2006. Mechanical aspects of apoptosome assembly. Curr Opin Cell Biol 18:677-684.
111. Shim H, Chun YS, Lewis BC, Dang CV. 1998. A unique glucose-dependent apoptotic pathway induced by c-Myc. Proc Natl Acad Sci USA 95:1511-1516.
112. Siskind LJ, Feinstein L, Yu T, Davis JS, Jones D, Choi J, Zuckerman JE, Tan W, Hill RB, Hardwick JM, Colombini M. 2008. Anti-apoptotic Bcl-2 family proteins disassemble ceramide channels. J Biol Chem 283:6622-6630.
113. Stacpoole PW, Wright EC, Baumgartner TG, Bersin RM, Buchalter S, Curry SH, Duncan CA, Harman EM, Henderson GN, Jenkinson S, et al. 1992. A controlled clinical trial of dichloroacetate for treatment of lactic acidosis in adults. The Dichloroacetate-Lactic Acidosis Study Group. N Engl J Med 327:1564-1569.
114. Stein RC, Joseph AE, Matlin SA, Cunningham DC, Fort HT, Coombes RC. 1992. A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemother Pharmacol 30:480-482.
115. Tahir SK, Yang X, Anderson MG, Morgan-Lappe SE, Sarthy AV, Chen J, Warner RB, Ng SC, Fesik SW, Elmore SW, Rosenberg SH, Tse C. 2007. Influence of Bcl-2 family member on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res 67:1176-1183.
116. Taketani S, Kohno H, Okuda M, Furukawa T, Tokunaga R. 1994. Induction of peripheral-type benzodiazepine receptors during differentiation of mouse erythroleukemia cells. A possible involvement of these receptors in heme biosynthesis. J Biol Chem 269:7527-7531. (Pubitemid 24217958)
117. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama H, Nakajima A. 2008. Metformin suppresses intestinal polyp growth in Apc-Min/+ mice. Cancer Sci 99:2136-2141.
118. Trachootham D, Zhang H, Zhang W, Feng L, Du M, Zhou Y, Chen Z, Pelicano H, Plunkett W, Wierda WG, Keating MJ, Huang P. 2008. Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism. Blood 112:1912-1922.
119. Tsujimoto Y, Cossman J, Jaffe E, Croce CM. 1985. Involvement of the bcl-2 gene in human follicular lymphoma. Science 228:1440-1443. (Pubitemid 15041322)
120. Tzung SP, Kim KM, Basañez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY, Hockenbery DM. 2001. Antimycin A mimics a celldeath-inducing Bcl-2 homology domain 3. Nat Cell Biol 3:183-191.
121. Ungar G, Freedman L, Shapiro SL. 1957. Pharmacological studies of a new oral hypoglycemic drug. Proc Soc Exp Biol Med 95:190-192.
122. Vali M, Vossen JA, Buijs M, Engles JM, Liapi E, Ventura VP, Khwaja A, Acha-Ngwodo O, Shanmugasundaram G, Syed L, Wahl RL, Geschwind JF. 2008. Targeting of VX2 rabbit liver tumor by selective delivery of 3-bromopyruvate: A biodistribution and survival study. J Pharmacol Exp Ther 327:32-37.
123. Van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis SN, Scott CL, Day CL, Cory S, Adams JM, Roberts AW, Huang DC. 2006. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 10:389-399.
124. Vander Heiden MG, Plas DR, Rathmell JC, Fox CJ, Harris MH, Thompson CB. 2001. Growth factors can influence cell growth and survival through effects on glucose metabolism. Mol Cell Biol 21:5899-5912.
125. Vander Heiden MG, Cantley LC, Thompson CB. 2009. Understanding the Warburg effect: The metabolic requirements of cell proliferation. Science 324:1029-1033.
126. Van Poznak C, Seidman AD, Reidenberg MM, Moasser MM, Sklarin N, Van Zee K, Borgen P, Gollub M, Bacotti D, Yao TJ, Bloch R, Ligueros M, Sonenberg M, Norton L, Hudis C. 2001. Oral gossypol in the treatment of patients with refractory metastatic breast cancer: A phase I/II clinical trial. Breast Cancer Res Treat 66:239-248.
127. Vaux DL, Cory S, Adams JM. 1988. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440-442.
128. Vousden KH, Ryan KM. 2009. p53 and metabolism. Nat Rev Cancer 9:691-700.
129. Walensky LD, Pitter K, Morash J, Oh KJ, Barbuto S, Fisher J, Smith E, Verdine GL, Korsmeyer SJ. 2006. A stapled BID BH3 helix directly binds and activates BAX. Mol Cell 24:199-210.
130. Wan KF, Chan SL, Sukumaran SK, Lee MC, Yu VC. 2008. Chelerythrine induces apoptosis through a Bax/Bak-independent mitochondrial mechanism. J Biol Chem 283:8423-8433.
131. Wang K, Yin XM, Chao DT, Milliman CL, Korsmeyer SJ. 1996. BID: A novel BH3 domain-only death agonist. Genes Dev 10:2859-2869. (Pubitemid 26394246)
132. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z. 2000. Structure-based discovery of an organic compound that binds bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA 97:7124-7129.
133. Wang L, Kong F, Kokoski CL, Andrews DW, Xing C. 2008. Development of dimeric modulators for anti-apoptotic Bcl-2 proteins. Bioorg Med Chem Lett 18:236-240.
134. Warburg O. 1956. On the origin of cancer cells. Science 123:309-314.
135. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB, Korsmeyer SJ. 2001. Proapoptotic BAX, BAK: A requisite gateway to mitochondrial dysfunction and death. Science 292:727-730.
136. Wendt MD, Shen W, Kunzer A, McClellan WJ, Bruncko M, Oost TK, Ding H, Joseph MK, Zhang H, Nimmer PM, Ng SC, Shoemaker AR, Petros AM, Oleksijew A, Marsh K, Bauch J, Oltersdorf T, Belli BA, Martineau D, Fesik SW, Rosenberg SH, Elmore SW. 2006. Discovery and structure-activity relationship of antagonists of B-cell lymphoma 2 family proteins with chemopotentiation activity in vitro and in vivo. J Med Chem 49:1165-1181.
137. Whitehouse S, Cooper RH, Randle PJ. 1974. Mechanism of activation of pyruvate dehydrogenase by dichloroacetate and other halogenated carboxylic acids. Biochem J 141:761-774.
138. Wise DR, DeBerardinis, Mancuso A, Sayed N, Zhang X-Y, Pfeiffer HK, Nissim I, Daikhin E, Yudkoff M, McMahon SB, Thompson CB. 2008. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 105:18782-18787.
139. Xu X, Leo C, Jang Y, Chan E, Padilla D, Huang BC, Lin T, Gururaja T, Hitoshi Y, Lorens JB, Anderson DC, Sikic B, Luo Y, Payan DG, Nolan GP. 2001. Dominant effector genetics in mammalian cells. Nat Genet 27:23-29.
140. Yin XM, Oltvai ZN, Korsmeyer SJ. 1994. BH1 and BH2 domains of Bcl-2 are required for inhibition of apoptosis and heterodimerization with Bax. Nature 369:321-323.
141. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. 2001. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 7:673-682.
142. Zhang Y, Kensler TW, Cho CG, Posner GH, Talalay P. 1994. Anticarcinogenic activities of sulforaphane and structurally related synthetic norbornyl isothiocyanates. Proc Natl Acad Sci USA 91:3147-3150. (Pubitemid 24130192)
143. Zhang YH, Bhunia A, Wan KF, Lee MC, Chan SL, Yu VC, Mok YK. 2006. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft. J Mol Biol 364:536-549.
144. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R, Preusser LC, Reinhart GA, Smith ML, Rosenberg SH, Elmore SW, Tse C. 2007. Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14:943-951.
145. Zheng Y, Shi Y, Tian C, Jiang C, Jin H, Chen J, Almasan A, Tang H, Chen Q. 2004. Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene 23:1239-1247.
146. Zhou YP, Pena JC, Roe MW, Mittal A, Levisetti M, Baldwin AC, Pugh W, Ostrega D, Ahmed N, Bindokas VP, Philipson LH, Hanahan D, Thompson CB, Polonsky KS. 2000. Overexpression of Bcl-xL in beta-cells prevents cell death but impairs mitochondrial signal for insulin secretion. Am J Physiol Endocrinol Metab 278:E340-E351.
147. Zou MH, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG IV, Schlattner U, Neumann D, Brownlee M, Freeman MB, Goldman MH. 2004. Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J Biol Chem 279:43940-43951.